文献速递血液淋巴病理

LMO2表达可区分T淋巴母细胞白血病/淋巴瘤与惰性T淋巴母细胞增殖

LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations.
PubMed 文献 · Histopathology · 2020-09-24

本研究回顾性分析7例惰性T淋巴母细胞增殖(iT-LBP)和13例T淋巴母细胞淋巴瘤(T-LBL),采用免疫组化检测LMO2表达。结果所有iT-LBP均阴性(0/7),92%的T-LBL表达LMO2(12/13),敏感性92%(CI 64-100%),特异性100%(CI 59-100%)。LMO2是排除iT-LBP的敏感且特异的标志物。

要点

  • iT-LBP与T-LBL形态和免疫表型高度重叠,鉴别困难。
  • LMO2在iT-LBP中全部阴性,在T-LBL中92%阳性。
  • LMO2免疫组化有助于排除iT-LBP。

核心结论

  • LMO2表达是排除惰性T淋巴母细胞增殖的敏感且特异的标志物。

研究设计与样本

  • 回顾性分析4个机构病理档案中7例iT-LBP和13例T-LBL病例,进行临床、形态、免疫表型和分子数据分析,所有病例行LMO2免疫组化染色。

主要发现

  • 所有iT-LBP病例LMO2阴性(0/7),92%的T-LBL病例表达LMO2(12/13)。
  • LMO2鉴别iT-LBP与T-LBL的敏感性为92%(置信区间64-100%),特异性为100%(置信区间59-100%)。
  • 5例新发iT-LBP病例的形态、免疫表型和分子特征与既往报道相似。

关键数值与推荐

  • LMO2免疫组化染色:iT-LBP阴性,T-LBL阳性率92%。
  • 敏感性92%(CI 64-100%),特异性100%(CI 59-100%)。

临床怎么用

  • 在鉴别iT-LBP与T-LBL时,可检测LMO2表达,阴性结果支持iT-LBP。

局限性

  • 样本量较小(iT-LBP 7例,T-LBL 13例),回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: An indolent T-lymphoblastic proliferation (iT-LBP) is a benign, reactive expansion of immature terminal deoxynucleotidyl transferase (TdT)-positive T cells found in extrathymic tissues. iT-LBP can be challenging to distinguish from malignant processes, specifically T-lymphoblastic lymphoma (T-LBL), given the overlapping clinical and histological features. Recently, it has been shown that LIM domain only 2 (LMO2) is overexpressed in T-LBL but not in reactive immature TdT+ T cells in the thymus. On the basis of these findings, the aim of this study was to investigate the expression of LMO2 by using immunohistochemistry and its role in differentiating iT-LBPs from T-LBLs. METHODS AND RESULTS: We retrospectively identified cases of iT-LBP and T-LBL from the pathology archives of four institutions. Seven iT-LBP cases (including five new cases that have not been reported in the literature) and 13 T-LBL cases were analysed. Clinical, morphological, immunophenotypic and molecular data were analysed. Immunohistochemical staining with LMO2 was performed on all iT-LBP and T-LBL cases. A review of five new iT-LBP cases showed similar morphological, immunophenotypic and molecular features to those of previously reported cases. All iT-LBP cases were negative for LMO2 (0/7), whereas 92% of T-LBL cases (12/13) expressed LMO2; the sensitivity was 92% (confidence interval 64-100%) and the specificity was 100% (confidence interval 59-100%). CONCLUSION: We confirm previously published findings that iT-LBP cases show highly overlapping morphological and immunophenotypic features with T-LBL. Importantly, LMO2 expression is a sensitive and specific marker with which to rule out iT-LBP.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Brar N, Butzmann A, Kumar J, et al. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology. 2020. PMID: 32526041. doi:10.1111/his.14176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。